Cyclo Therapeutics- Warrants (14/11/2025) Profit Margin

Cyclo Therapeutics- Warrants (14/11/2025) posts a profit margin of -2848.16% as of September 2024. That compares with -2019.93% in the prior-year period — down 41.0% year over year. That is below the Healthcare sector average of 15.29%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Cyclo Therapeutics- Warrants (14/11/2025)'s profit margin was -2019.93%. The latest reading is -2848.16% — a 41.0% year-over-year decrease (period ending September 2024). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.29% is typical. Cyclo Therapeutics- Warrants (14/11/2025)'s -2848.16% is lower that level. That is roughly 18724.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Cyclo Therapeutics- Warrants (14/11/2025)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -2848.16% as of September 2024; use YoY and peer views to separate noise from signal.

Context for CYTHW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.29%), and (3) consistency with growth and profitability. This page covers the first two; Cyclo Therapeutics- Warrants (14/11/2025)'s other metric pages and overview cover the third.